- Home
- SLM vs TFX Comparison
SLM vs TFX Comparison
Compare SLM & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLM
- TFX
- Stock Information
- Founded
- SLM 1972
- TFX 1943
- Country
- SLM United States
- TFX United States
- Employees
- SLM N/A
- TFX N/A
- Industry
- SLM Finance: Consumer Services
- TFX Medical/Dental Instruments
- Sector
- SLM Finance
- TFX Health Care
- Exchange
- SLM Nasdaq
- TFX Nasdaq
- Market Cap
- SLM 6.7B
- TFX 5.3B
- IPO Year
- SLM N/A
- TFX N/A
- Fundamental
- Price
- SLM $33.41
- TFX $116.88
- Analyst Decision
- SLM Buy
- TFX Hold
- Analyst Count
- SLM 10
- TFX 10
- Target Price
- SLM $33.10
- TFX $176.50
- AVG Volume (30 Days)
- SLM 2.2M
- TFX 522.9K
- Earning Date
- SLM 07-24-2025
- TFX 07-31-2025
- Dividend Yield
- SLM 1.55%
- TFX 1.17%
- EPS Growth
- SLM N/A
- TFX N/A
- EPS
- SLM 2.78
- TFX 3.20
- Revenue
- SLM $1,449,130,000.00
- TFX $3,010,144,000.00
- Revenue This Year
- SLM $7.53
- TFX $2.98
- Revenue Next Year
- SLM $9.62
- TFX $4.72
- P/E Ratio
- SLM $12.03
- TFX $36.39
- Revenue Growth
- SLM N/A
- TFX 0.29
- 52 Week Low
- SLM $19.39
- TFX $115.94
- 52 Week High
- SLM $34.97
- TFX $249.91
- Technical
- Relative Strength Index (RSI)
- SLM 56.02
- TFX 41.62
- Support Level
- SLM $33.01
- TFX $116.32
- Resistance Level
- SLM $34.97
- TFX $121.75
- Average True Range (ATR)
- SLM 0.76
- TFX 2.88
- MACD
- SLM 0.06
- TFX 0.10
- Stochastic Oscillator
- SLM 61.10
- TFX 11.71
About SLM SLM Corporation
SLM Corp is an education solutions company. It business is to originate and service loans to students and their families to finance the cost of their education. The provide Private Education Loans to mean education loans to students or their families that are not made, insured, or guaranteed by any state or federal government.
About TFX Teleflex Incorporated
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.